Article
Pharmacology & Pharmacy
Hongmei Dong, Liang Du, Songwang Cai, Wan Lin, Chaoying Chen, Matthew Still, Zhimeng Yao, Robert P. Coppes, Yunlong Pan, Dianzheng Zhang, Shegan Gao, Hao Zhang
Summary: This study reveals the correlation between PTPRO and lapatinib resistance in ERBB2-positive breast cancer, suggesting that PTPRO can serve as an independent prognostic indicator and upregulating PTPRO can reverse the resistance to lapatinib.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Edward Seung, Zhen Xing, Lan Wu, Ercole Rao, Virna Cortez-Retamozo, Beatriz Ospina, Liqing Chen, Christian Beil, Zhili Song, Bailin Zhang, Mikhail Levit, Gejing Deng, Andrew Hebert, Patrick Kirby, Aiqun Li, Emma-Jane Poulton, Rita Vicente, Audrey Garrigou, Peter Piepenhagen, Greg Ulinski, Michele Sanicola-Nadel, Dinesh S. Bangari, Huawei Qiu, Lily Pao, Dmitri Wiederschain, Ronnie Wei, Zhi-yong Yang, Gary J. Nabel
Summary: A trispecific antibody targeting HER2 and T cells can inhibit breast cancer cell proliferation by stimulating CD4 T cells, and induce tumor regression in a humanized mouse model.
Article
Oncology
Chewei Anderson Chang, Jayu Jen, Shaowen Jiang, Azin Sayad, Arvind Singh Mer, Kevin R. Brown, Allison M. L. Nixon, Avantika Dhabaria, Kwan Ho Tang, David Venet, Christos Sotiriou, Jiehui Deng, Kwok-Kin Wong, Sylvia Adams, Peter Meyn, Adriana Heguy, Jane A. Skok, Aristotelis Tsirigos, Beatrix Ueberheide, Jason Moffat, Abhyudai Singh, Benjamin Haibe-Kains, Alireza Khodadadi-Jamayran, Benjamin G. Neel
Summary: Resistance to targeted therapies in HER2-positive breast cancer is often attributed to the presence of drug-tolerant persisters (DTPs). This study reveals that HER2 TKI treatment leads to the emergence of DTPs with different transcriptomes, and these DTPs are originated from pre-DTP cells that cycle stochastically. The findings provide insights into the ontogeny of DTPs and potential vulnerabilities for therapeutic targeting.
Article
Medicine, Research & Experimental
Myrto Moutafi, Charles J. Robbins, Vesal Yaghoobi, Aileen Fernandez, Sandra Martinez-Morilla, Vasiliki Xirou, Yalai Bai, Yan Song, Patricia Gaule, Joseph Krueger, Kenneth Bloom, Salisha Hill, Daniel C. Liebler, Regan Fulton, David L. Rimm
Summary: The efficacy of the antibody drug conjugate Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests the need for revision of the conventional HER2 assays. In this study, an optimized dynamic range for unamplified HER2 detection in breast cancer was determined and a quantitative assay to stratify HER2 expression in unamplified cases was designed. The application of this assay to a large number of breast cancer cases demonstrated its potential for selecting optimal patients for T-DXd treatment.
LABORATORY INVESTIGATION
(2022)
Article
Oncology
Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel
Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.
Article
Biochemistry & Molecular Biology
Katia Cortese, Marco Ponassi, Aldo Profumo, Gabriela Coronel Vargas, Erika Iervasi, Maria Cristina Gagliani, Grazia Bellese, Sara Tavella, Patrizio Castagnola
Summary: This study revealed shared mechanisms in acquired Tz resistance in breast cancer cells, including alterations in lipid metabolism, organophosphate biosynthesis, and macromolecule methylation. These findings suggest potential targets for therapeutic interventions to overcome Tz resistance and improve patient outcomes.
Article
Genetics & Heredity
Rabi Murad, Arabo Avanes, Xinyi Ma, Shuhui Geng, Ali Mortazavi, Jamil Momand
Summary: The study revealed increased chromatin accessibility within PPP1R1B in trastuzumab-resistant breast cancer cells, associated with its t-Darpp transcript increase, pointing to a possible mechanism for its activation in resistant cells.
Article
Oncology
Guilherme Nader-Marta, Veronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Summary: The sub-analysis of the ALTTO trial demonstrates that patients with small node-negative breast cancer treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Summary: PIK3CA mutations were associated with shorter PFS, while higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C compared with L+C.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Marcela Carausu, Matthieu Carton, Veronique Dieras, Thierry Petit, Severine Guiu, Anthony Goncalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sebastien Frenel, Audrey Mailliez, Michael Chevrot, Luc Cabel
Summary: Evidence suggests that patients with HR+/ERBB2+ metastatic breast cancer have different clinical characteristics and outcomes. The association of HR status and first-line inclusion of ET with outcomes among patients with ERBB2+ MBC was evaluated. ET-containing first-line regimens may be associated with benefits in a subgroup of patients with HR+/ERBB2+ MBC.
Article
Oncology
Mary L. Disis, Katherine A. Guthrie, Ying Liu, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Yushe Dang, Lupe G. Salazar
Summary: The study aimed to determine the safety and immunogenicity of a plasmid-based vaccine encoding the ERBB2 intracellular domain. The results showed that vaccination with a 100-mu g dose of the vaccine could induce ERBB2-specific type 1 T cells in most patients with ERBB2-expressing breast cancer, and the highest dose vaccine was associated with the greatest incidence of persistent DNA at the injection site. This study is highly significant for the development of vaccine therapy targeting ERBB2 immunity in breast cancer.
Article
Cardiac & Cardiovascular Systems
Anthony F. Yu, Zachary R. Moore, Chaya S. Moskowitz, Jennifer E. Liu, Chau T. Dang, Lakshmi Ramanathan, Kevin C. Oeffinger, Richard M. Steingart, Adam M. Schmitt
Summary: This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD. Quantification of cardiomyocyte cfDNA holds promise as a predictive biomarker for risk stratification of CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy and requires further validation.
Article
Cell Biology
Andreas A. Hombach, Christine Ambrose, Roy Lobb, Paul Rennert, Hinrich Abken
Summary: The efficacy of CD19-specific CAR T cells in the treatment of leukemia/lymphoma relies on the properties of the CAR and the presence of healthy B cells. This study shows that the same CAR can be used to target solid tumors, such as ErbB2(+) carcinoma, by redirecting CD19 CAR T cells towards the ErbB2(+) cells. The ErbB2-redirected CD19 CAR T cells have efficient killing capacity and improved anti-tumor activities when CD19(+) B cells are present.
Article
Public, Environmental & Occupational Health
Zhiyuan Tang, Xin Xu, Jie Gao, Ling Chen, Qiuyan Zhu, Jinli Wang, Xiaoyu Yan, Bohua Chen, Yumei Zhu
Summary: Based on the economic evaluation, margetuximab plus chemotherapy is not likely to be cost-effective for women with pretreated ERBB2-positive advanced breast cancer in the United States and China. However, price reduction can effectively improve the insufficient cost-effectiveness.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Oncology
Josee-Lyne Ethier, Danielle Desautels, Andrew Robinson, Eitan Amir, Weidong Kong, Christopher M. Booth
Summary: This study examined the use of pertuzumab and T-DM1 in routine clinical practice in Ontario, Canada. The survival outcomes of patients treated with pertuzumab and T-DM1 in routine practice appeared to be inferior to results from pivotal clinical trials. Further research is needed to understand the effectiveness of T-DM1 after pertuzumab exposure.
Article
Biochemistry & Molecular Biology
Nicole E. Brown, Devrishi Goswami, Mary Rose Branch, Suneela Ramineni, Eric A. Ortlund, Patrick R. Griffin, John R. Hepler
JOURNAL OF BIOLOGICAL CHEMISTRY
(2015)
Review
Biochemistry & Molecular Biology
Samantha M. Prezioso, Nicole E. Brown, Joanna B. Goldberg
MOLECULAR MICROBIOLOGY
(2017)
Article
Biochemistry & Molecular Biology
Christopher P. Vellano, Nicole E. Brown, Joe B. Blumer, John R. Hepler
JOURNAL OF BIOLOGICAL CHEMISTRY
(2013)
Article
Medicine, Research & Experimental
Kia E. Bryant, Yan Yuan, Melissa Engle, Ekaterina Kurbatova, Cynthia Allen-Blige, Kumar Batra, Nicole E. Brown, Kuo Wei Chiu, Howard Davis, Mascha Elskamp, Melissa Fagley, Pamela Fedrick, Kimberley N. C. Hedges, Kim Narunsky, Joanita Nassali, Mimi Phan, Ha Phan, Anne E. Purfield, Jessica N. Ricaldi, Kathleen Robergeau-Hunt, William C. Whitworth, Erin E. Sizemore
Summary: This report discusses the implementation of central monitoring during a large phase 3 clinical trial, utilizing primary study data for real-time checks and quality assessments to ensure protocol compliance and accurate data reporting. The use of a five-tiered approach for data review and reporting allowed for efficient detection and resolution of quality challenges, leading to improved prioritization of data and more effective management of study sites.
CONTEMPORARY CLINICAL TRIALS
(2021)
Article
Immunology
Nicole E. Brown, Amy E. Blain, Kari Burzlaff, Lee H. Harrison, Susan Petit, William Schaffner, Chad Smelser, Ann Thomas, Lori Triden, James P. Watt, Tracy Pondo, Melissa J. Whaley, Fang Hu, Xin Wang, Sara Oliver, Heidi M. Soeters
Summary: The introduction of Hib conjugate vaccines in the United States has changed the epidemiology of invasive H. influenzae disease, with a focus on racial disparities. While nontypeable H. influenzae causes the largest burden overall, AI/AN populations experience disproportionately high rates of Hia and Hib, particularly among children under 5 years old. Prevention tools are needed to address these disparities and the increasing incidence of Hia in other communities.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Nicole E. Brown, Amanda K. Lyons, Amy J. Schuh, Megan M. Stumpf, Jennifer L. Harcourt, Azaibi Tamin, Mohammad Ata Ur Rasheed, Lisa Mills, Sandra N. Lester, Natalie J. Thornburg, Kenny Nguyen, Veronica Costantini, Jan Vinje, Jennifer Y. Huang, Sarah E. Gilbert, Paige Gable, Susan Bollinger, Sarah Sabour, Elizabeth Beshearse, Diya Surie, Caitlin Biedron, Christopher J. Gregory, Nakia S. Clemmons, Brett Whitaker, Melissa M. Coughlin, Kathryn A. Seely, Kelley Garner, Trent Gulley, Tafarra Haney, Atul Kothari, Naveen Patil, Alison Laufer Halpin, L. Clifford McDonald, Preeta K. Kutty, Allison C. Brown
Summary: SARS-CoV-2-specific immune responses were detected in both plasma and gingival crevicular fluid (GCF) of nursing home residents after natural infection, with similar kinetics of antibody responses. GCF, a noninvasive method, may be useful for detecting and monitoring immunologic responses in populations unable or unwilling to be phlebotomized.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2022)
Article
Immunology
Keegan C. Rudmann, Nicole E. Brown, Amy B. Rubis, Meagan Burns, April Ramsey, Denise De Las Nueces, Tasha Martin, Meghan Barnes, Emily Spence Davizon, Adam C. Retchless, Caelin Potts, Xin Wang, Susan Hariri, Lucy A. McNamara
Summary: Several IMD outbreaks caused by Neisseria meningitidis have occurred among people experiencing homelessness (PEH). This study compared the incidence and characteristics of IMD among PEH and non-PEH in the United States. The results showed that PEH are at increased risk for IMD, with a higher incidence compared to non-PEH.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Critical Care Medicine
Ekaterina V. Kurbatova, Patrick P. J. Phillips, Susan E. Dorman, Erin E. Sizemore, Kia E. Bryant, Anne E. Purfield, Jessica Ricaldi, Nicole E. Brown, John L. Johnson, Carole L. Wallis, Joseph P. Akol, Oksana Ocheretina, Nguyen Van Hung, Harriet Mayanja-Kizza, Madeleine Lourens, Rodney Dawson, Nguyen Viet Nhung, Samuel Pierre, Yeukai Musodza, Justin Shenje, Sharlaa Badal-Faesen, Stalz Charles Vilbrun, Ziyaad Waja, Lakshmi Peddareddy, Nigel A. Scott, Yan Yuan, Stefan V. Goldberg, Susan Swindells, Richard E. Chaisson, Payam Nahid
Summary: A standardized method called possible poor treatment response (PPTR) was developed to determine the efficacy endpoints in the treatment of pulmonary tuberculosis. The use of PPTR process helped to minimize bias in efficacy endpoint assessment and obtain relevant data for outcome determination. The study found that PPTR approach improved the accuracy of evaluating treatment efficacy, discriminating between related and unrelated outcomes, and facilitating pooled analysis.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Immunology
Guillermo Sanchez, Constance L. Bourne, Sherri L. Davidson, Mark Ellis, Leora R. Feldstein, Katherine Fay, Nicole E. Brown, Evelyn F. Geeter, Lytasha L. Foster, Charlotte Gilmore, Mary G. McIntyre, Burnestine Taylor, Srinivasan Velusamy, Sopio Chochua, Almea M. Matanock
Summary: The outbreak of pneumococcal disease in a state prison in Alabama, USA was caused by Streptococcus pneumoniae serotype 12F. Close living quarters, substance use, and underlying conditions likely contributed to disease risk. Prophylaxis for close contacts included azithromycin and 23-valent pneumococcal polysaccharide vaccine to reduce infection risk.
EMERGING INFECTIOUS DISEASES
(2021)
Letter
Immunology
Nicole E. Brown, Jonathan Bryant-Genevier, Uptala Bandy, Carol A. Browning, Abby L. Berns, Mary Dott, Michael Gosciminski, Sandra N. Lester, Ruth Link-Gelles, Daniela N. Quilliam, James Sejvar, Natalie J. Thornburg, Bernard J. Wolff, John Watson
EMERGING INFECTIOUS DISEASES
(2020)
Article
Pharmacology & Pharmacy
Nicole E. Brown, Nevin A. Lambert, John R. Hepler
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2016)
Article
Pharmacology & Pharmacy
Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci
Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas
Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.
BIOCHEMICAL PHARMACOLOGY
(2024)
Article
Pharmacology & Pharmacy
Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li
Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.
BIOCHEMICAL PHARMACOLOGY
(2024)
Review
Pharmacology & Pharmacy
Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang
Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.
BIOCHEMICAL PHARMACOLOGY
(2024)